A Unique Opportunity to Develop Differentiated Therapeutics and Diagnostics Across Inflammation and Cancer.
ImmunoOne offers flexible licensing models designed to maximize the value of the oxMIF platform and its associated assets. Depending on partner priorities, access is available at the asset, platform, or portfolio level.
Your Trusted Licensing Partner.
We support the future development by providing ImmunoOne's scientific and development expertise.
Structured development roadmaps available
Preclinical data packages with defined go/no-go criteria
Mechanistic expertise and translational strategy
Proprietary anti-oxMIF antibody portfolio with full IP coverage
Your Trusted Licensing Partner.
We support the future development by providing ImmunoOne's scientific and development expertise.
Proprietary anti-oxMIF antibody portfolio with full IP coverage
Mechanistic expertise and translational strategy
Preclinical data packages with defined go/no-go criteria
Structured development roadmaps available
Licensing Models
Asset Licensing
Access to selected oxMIF-based antibody assets for development in specific indications, enabling targeted integration into existing pipelines.
Platform Licensing
Broad access to the oxMIF platform, including multiple assets and underlying know-how, supporting therapeutic development across a range of indications.
Full Portfolio Acquisition
Opportunity to acquire the complete oxMIF asset portfolio, including all associated rights and data, enabling full strategic control and development.
Work With OncoOne
Advancing pretargeted radiopharmaceutical therapies together.
Our science-driven collaborations accelerate clinical translation and expand the PreTarg-it® platform across oncology indications.
Have We Piqued Your Interest?
Get in touch
Labs and Offices
OncoOne Research & Development GmbH
Karl-Farkas-Gasse 22
1030 Vienna, Austria
